Sangamo Therapeutics, Inc. (SGMO) Expected to Announce Earnings of -$0.20 Per Share
Equities analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will post earnings of ($0.20) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sangamo Therapeutics’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.26). Sangamo Therapeutics reported earnings per share of ($0.27) during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.9%. The business is scheduled to announce its next earnings report on Wednesday, October 25th.
On average, analysts expect that Sangamo Therapeutics will report full-year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($1.04) to ($0.74). For the next year, analysts expect that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.23) to ($0.02). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm had revenue of $8.30 million during the quarter, compared to analyst estimates of $5.82 million. During the same period last year, the firm posted ($0.38) earnings per share. Sangamo Therapeutics’s revenue for the quarter was up 124.3% compared to the same quarter last year.
SGMO has been the subject of a number of recent research reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, September 14th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Friday, August 18th. BidaskClub downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. ValuEngine raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Finally, Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $14.40.
Sangamo Therapeutics (NASDAQ SGMO) traded up 1.57% on Wednesday, hitting $16.15. 1,357,281 shares of the company were exchanged. The stock’s market capitalization is $1.35 billion. Sangamo Therapeutics has a 52-week low of $2.65 and a 52-week high of $17.06. The stock’s 50-day moving average price is $13.82 and its 200-day moving average price is $8.97.
COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/11/sangamo-therapeutics-inc-sgmo-expected-to-announce-earnings-of-0-20-per-share.html.
In other news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $15.25, for a total transaction of $228,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William R. Ringo sold 31,000 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total value of $445,470.00. Following the transaction, the director now owns 31,800 shares of the company’s stock, valued at $456,966. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 87,474 shares of company stock valued at $1,169,009. Company insiders own 5.50% of the company’s stock.
A number of institutional investors have recently made changes to their positions in SGMO. Blair William & Co. IL boosted its holdings in Sangamo Therapeutics by 4.3% during the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 500 shares during the period. Aperio Group LLC purchased a new position in Sangamo Therapeutics during the 2nd quarter valued at about $108,000. Principal Financial Group Inc. boosted its holdings in Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 832 shares during the period. Virtu KCG Holdings LLC purchased a new position in Sangamo Therapeutics during the 2nd quarter valued at about $124,000. Finally, Fox Run Management L.L.C. purchased a new position in Sangamo Therapeutics during the 2nd quarter valued at about $126,000. Institutional investors own 63.43% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.